MBRX - Moleculin Biotech, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.69
+0.04 (+2.42%)
As of 3:06PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.65
Open1.65
Bid1.68 x 1100
Ask1.70 x 2900
Day's Range1.64 - 1.69
52 Week Range1.50 - 3.34
Volume145,063
Avg. Volume251,580
Market Cap45.396M
Beta-0.81
PE Ratio (TTM)N/A
EPS (TTM)-0.57
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Trade prices are not sourced from all markets
  • GlobeNewswire8 days ago

    Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2018

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, today announced its financial results for the second quarter ended June 30, 2018. Additionally, the Company announced potential upcoming milestones and recent corporate developments. Walter Klemp, Chairman and CEO of Moleculin, said, “During the second quarter, and the first half of 2018, we continued to make measurable progress in achieving important milestones in our three core disruptive technologies and six oncology drug candidates.

  • GlobeNewswire12 days ago

    Moleculin Seeks Approval from Polish Regulatory Agency for Skin Cancer Clinical Trial

    HOUSTON, Aug. 09, 2018-- Moleculin Biotech, Inc.,, a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The ...

  • GlobeNewswire21 days ago

    Moleculin Announces Enrollment Opens for Brain Tumor Trial of WP1066

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced enrollment has opened for a physician-sponsored clinical trial of WP1066 for the treatment of glioblastoma and brain metastases in adults. “We have been eagerly awaiting the beginning of this physician sponsored clinical trial,” commented Walter Klemp, Chairman and CEO of Moleculin.

  • GlobeNewswirelast month

    Moleculin Expects to Meet FDA IND Filing Requirements for its Pancreatic Cancer Drug Candidate with Development Work in Australia

    “Based on preclinical testing, we believe the discovery of WP1732, a fully water-soluble STAT3 inhibitor,  has the potential to be a breakthrough discovery for rare and difficult to treat cancers. As a result of our preclinical testing, we have recieved  multiple requests to commence clinical trials and we are pleased to be taking the next steps in preparing for the appropriate clinical work,” commented Walter Klemp, Chairman and CEO of Moleculin.

  • GlobeNewswirelast month

    Moleculin Expands Operations to Australia; Taps R&D Incentive Program Capped at $20,000,000 AUD Turnover

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has formed Moleculin Australia Pty. Ltd., a wholly-owned subsidiary to oversee preclinical development in Australia. Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on discoveries made at M.D. Anderson Cancer Center.

  • GlobeNewswire2 months ago

    Moleculin Selected for the Russell Microcap Index

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced the Company was selected to be added to the Russell Microcap® Index effective after the U.S. market opened on June 25, 2018, when the Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes. “We are pleased that Moleculin was selected to be included in the Russell Microcap Index,” commented Walter Klemp, Chairman and CEO of Moleculin. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.

  • GlobeNewswire2 months ago

    Moleculin Announces $2.3 Million Registered Direct Offering Priced At-the-Market

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that it has entered into a definitive agreement with institutional investors for a registered direct offering of securities with gross proceeds of approximately $2.3 million. In connection with the offering, the Company will issue 1,092,636 registered shares of common stock at a purchase price of $2.105 per share.  Concurrently in a private placement, for each share of common stock purchased by an investor, such investor will receive from the Company an unregistered warrant to purchase 0.65 of a share of common stock.  The warrants have an exercise price of $2.02 per share, will be exercisable six months from the date of issuance, and will expire five years from the initial exercise date.

  • Benzinga2 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Winnebago Industries, Inc. (NYSE: WGO ) stock was ...

  • GlobeNewswire2 months ago

    Moleculin Receives Approval for Leukemia Clinical Trial

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has received Polish National Office approval to begin its second Phase I/II clinical trial to study Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (“AML”). “This approval is a significant step forward to be able to treat additional patients with AML and to generate positive clinical data regarding Annamycin,” commented Walter Klemp, Chairman and CEO of Moleculin.

  • GlobeNewswire2 months ago

    Moleculin Targets accelerated FDA approval of WP1732; Pursues Development for Ocular Tumors

    Moleculin Biotech, Inc. (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that it has entered into an agreement with the Jagiellonian University in Krakow, Poland, for the development of its STAT3 inhibitor, WP1732, for the treatment of ocular tumors. “Today there are very limited options for the treatment of ocular tumors," commented Walter Klemp, Chairman and CEO of Moleculin.

  • GlobeNewswire2 months ago

    Moleculin’s Breakthrough Discovery of a New Molecule for Cancer Treatment Advances to Development Agreement with the University of Iowa

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that has entered into an agreement with The University of Iowa Pharmaceuticals for the development of a formulation for WP1732.

  • ACCESSWIRE3 months ago

    Nektar Therapeutics and Three Additional Biotech Stocks on Our Research Desk’s Radar

    Stock Research Monitor: MBRX, OGEN, and OTIC LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want a free Stock Review on NKTR sign up now at www.wallstequities.com/registration . On Friday, May 25, 2018, ...

  • GlobeNewswire3 months ago

    Moleculin Invited to Present to International BioForum 2018 Conference

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that its CEO, Walter Klemp, was asked to address the 2018 BioForum Conference in Łódź, Poland. The Moleculin Chairman and CEO was asked to give a lecture on Polish-American Innovation Bridge: Bringing validated innovations from USA to Poland.

  • Who Owns Most Of Moleculin Biotech Inc (NASDAQ:MBRX)?
    Simply Wall St.3 months ago

    Who Owns Most Of Moleculin Biotech Inc (NASDAQ:MBRX)?

    Today, I will be analyzing Moleculin Biotech Inc’s (NASDAQ:MBRX) recent ownership structure, an important but not-so-popular subject among individual investors. The impact of a company’s ownership structure affects both itsRead More...

  • Marketwired4 months ago

    Moleculin Announces New Data for Immuno-Stimulating Drug to be Presented at International Conference

    Moleculin Biotech, Inc., , a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System......

  • ACCESSWIRE4 months ago

    Wired News – Spectrum Pharma Reported Update Data from MD Anderson’s Phase-2 Data Assessing Poziotinib in EGFR Exon 20 Mutant NSCLC Patients

    Stock Monitor: Moleculin Biotech Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 12, 2018 / Active-Investors.com has just released a free research report on Spectrum Pharma, Inc. (NASDAQ: SPPI ...

  • Marketwired5 months ago

    Moleculin Announces Patients Treated in FDA Approved Phase I/II Annamycin Clinical Trial

    Moleculin Biotech, Inc., , a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System......

  • Marketwired5 months ago

    Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2017

    Moleculin Biotech, Inc. , a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System......

  • Marketwired5 months ago

    Moleculin Enters Agreement with Seidman Cancer Center to Conduct Leukemia Clinical Trials

    Moleculin Biotech, Inc., , a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System......

  • Marketwired5 months ago

    Moleculin Announces Grant-Funded Collaboration to Expand Understanding of New Discovery

    Moleculin Biotech, Inc. , a clinical stage pharmaceutical company focused on the development of oncology drug candidates, some of which are based on license agreements with The University of Texas System......

  • Marketwired6 months ago

    Moleculin to Present at the 30th Annual ROTH Conference Tuesday, March 13, 2018

    Moleculin Biotech, Inc., , a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas......

  • Benzinga6 months ago

    The Market In 5 Minutes: Trump, Tariffs, Trade Wars And More

    IN THE NEWS Steel and aluminum stocks are popping while the rest of the market crashes after President Donald Trump said he will be announcing new steel and aluminum tariffs as early as next week: Link ...